The present invention provides methods and kits to obtain an early evaluation of mortality risk and help therapeutic decisions for patients in severe sepsis with two organ failures, for example for patients in septic shock. The invention is based on the measure of the level of S100A8/A9 complex in plasma, since a level of S100A8/A9 above a predetermined threshold is indicative of a bad prognosis and a level of S100A8/A9 below said predetermined threshold is indicative of a good prognosis.
展开▼